Navigation Links
Femtogram Sensitivity of the Antipsychotic Drugs Raclopride and Ritanserin Using a Varian 1200L LC/MS/MS

J. Beck and C. Schmidt
Varian, Inc.

Introduction

Ritanserin (Tisterton) is a serotonin-2 antagonist drug shown to be effective in the treatment of anxiety and depression1 while Raclopride acts as a dopamine D2 receptor antagonist.2 These two compounds were used to demonstrate low-level sensitivity of the Varian 1200L LC/MS/MS in selected reaction monitoring mode (SRM). Studies have shown LC/MS to be a useful tool in the quantitation of low levels of Raclopride.3

Instrumentation

Varian 1200L LC/MS/MS equipped with ESI source

Materials and Reagents

Ritanserin ordered from Sigma-Aldrich Corp.,Catalog Number R-103

S-(-)-Raclopride ordered from Sigma-Aldrich Corp.,Catalog Number R-121

All other chemicals are reagent grade or HPLC grade

Sample Preparation

Milligram quantities were prepared and dissolved in a 50:50 mixture of acetonitrile/water with 0.1% formic acid. Serial dilutions were made from each stock solution prior to flow injection analysis (FIA). Samples were injected into a mobile phase of 50:50 acetonitrile/0.1% formic acid which was pumped directly into the mass spectrometer at 0.2 mL/min. A 5 μL loop was used for the injections and the injections were repeated five times for each concentration level.

Results and Discussion

Raclopride Five replicates at five different concentration levels were run. FIA injections of Raclopride at its lowest detectable limit, 100 pg/mL (500 fg on-column), is shown in Figure 1. At the lowest level, the S/N ratio is approximately 10:1 for the raw data. Also, a plot at a higher concentration of 10 ng/mL is included for comparison (Figure 2). The calibration cur
'"/>

Source:


Page: All 1 2

Related biology technology :

1. Improved Sensitivity for Staining RNA with SYBR Gold Stain
2. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
3. Increase the Power and Sensitivity for Your cDNA Synthesis with the New Transcriptor Reverse Transcriptase
4. Increased Sensitivity in Microarray Analysis
5. Maintaining High Sensitivity when Working with Small-Volume Samples
6. High Sensitivity, Wide Dynamic Range, Horseradish Peroxidase (HRP) ELISA Using the LMax Microplate Luminometer (MaxLine Application Note #41)
7. Sensitivity and Quantitation using a Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer
8. Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery
9. Trace Analysis Optimizing Sensitivity Finnigan Surveyor PDA Detector
10. A Screen of shRNAs Targeting Tumor Suppressor Genes to Identify Factors Involved in Paclitaxel Sensitivity
11. Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method
Post Your Comments:
(Date:7/22/2014)... Ore. , July 22, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today announced that ... before the open of U.S. financial markets on July ... Semler will host a conference call at 11 a.m. ...
(Date:7/22/2014)... 2014 Holomic is expanding its ... of its fluorescent immunoassay reader, the HRDR-300, at ... in Chicago, July 28-31, 2014. Available in both ... HRDR-300 is a highly sensitive, low-cost fluorescent reader ... lateral flow immunoassays with high sensitivity and accuracy. ...
(Date:7/22/2014)... Dr. Williams says, “Bush has joined the constantly ... greatest health care system in the world is too ... trying to serve the public. Unfortunately, Bush has also ... enormous system that none of them can first describe ... of Open Letters ( http://is.gd/wdU2CM ) provides a critique ...
(Date:7/21/2014)... College of Arts and Sciences has received a ... nanoparticles. , Mathew M. Maye, associate professor of ... from the National Science Foundation (NSF). The award ... nanostructures, the results of which may impact gas ... , Maye,s approach is novel, in that ...
Breaking Biology Technology:Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2
... , , ROCKVILLE, Md., July 21 ... appointment of John J. Trizzino as Senior Vice President, International ... Trizzino will report directly to Dr. Rahul Singhvi, Novavax,s President ... managing the company,s international alliances with pharmaceutical companies and all ...
... ... is pleased the U.S. Environmental Protection Agency will allow farmers the ability to improve upon ... for SmartStax, an insect-protection and weed control platform in corn, to 5 percent in the ... ...
... , , NEWARK, N.J., July 21 ... a specialty chemical technology based Life Science Company announced ... protocol testing, BioNeutral,s Ygiene(TM) Hospital Grade Antimicrobial passed the ... all 5.4 million spores of Clostridium difficile ...
Cached Biology Technology:Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances 2EPA Refuge Determination Positive for the Environment 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 3
(Date:7/22/2014)... team from the National Institute of Standards and ... demonstrated a dramatically improved technique for analyzing biological ... "signatures." The new NIST technique is an advanced ... but one that delivers signals that are 10,000 ... and 100 times stronger than obtained from comparable ...
(Date:7/22/2014)... reputation as disease causing agents, some viruses can ... to shape the world we live in today, ... Academy of Microbiology. , "Viruses participate in essential ... the planet, from contributing to biogeochemical cycles, shaping ... states Marilyn Roossinck of Pennsylvania State University, a ...
(Date:7/22/2014)... promise for treating damaged organs and tissues, but with ... their effectiveness. New methods are being developed and tested ... after transplantation, as described in a Review article in ... Mary Ann Liebert, Inc., publishers. The article is available ... website . , In the article ,Preconditioning ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Report on viruses looks beyond disease 2
... Researchers speaking in the first plenary session of the ... (IAS 2011) have today offered insights into current and ... developments over the past two years are beginning ... policy. The presentations reflect the breadth of expertise ...
... trailing a long length of rope behind you is not ... to manoeuvre, and can get tangled up or stuck on ... apart during cell division. The chromosomes are pulled by their ... Just like climbers carry their rope coiled up, cells make ...
... PHILADELPHIA The use of trastuzumab, chemotherapy and ... improved survival from the time central nervous system metastases ... researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now ... chemotherapy, even if cancer spreads to the brain." ...
Cached Biology News:Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 2Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 3Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy 4Keeping it together 2Trastuzumab and chemotherapy improved survival in HER2-postive breast and brain cancer patients 2